JP2010532380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532380A5 JP2010532380A5 JP2010515219A JP2010515219A JP2010532380A5 JP 2010532380 A5 JP2010532380 A5 JP 2010532380A5 JP 2010515219 A JP2010515219 A JP 2010515219A JP 2010515219 A JP2010515219 A JP 2010515219A JP 2010532380 A5 JP2010532380 A5 JP 2010532380A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- formula
- nitrogen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 115
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 82
- 229910052757 nitrogen Inorganic materials 0.000 claims description 57
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 46
- 239000001301 oxygen Chemical group 0.000 claims description 46
- 229910052760 oxygen Inorganic materials 0.000 claims description 46
- 125000002619 bicyclic group Chemical group 0.000 claims description 45
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 43
- 229910052717 sulfur Chemical group 0.000 claims description 43
- 239000011593 sulfur Chemical group 0.000 claims description 43
- 125000005842 heteroatom Chemical group 0.000 claims description 42
- 125000002950 monocyclic group Chemical group 0.000 claims description 36
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- -1 oxadiadiolyl Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 208000020084 Bone disease Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
- 208000019838 Blood disease Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 4
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
- 230000001066 destructive effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000014951 hematologic disease Diseases 0.000 claims description 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 125000005306 thianaphthenyl group Chemical group 0.000 claims description 4
- 125000004306 triazinyl group Chemical group 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000002584 immunomodulator Effects 0.000 claims description 3
- UWCWUCKPEYNDNV-LBPRGKRZSA-N 2,6-dimethyl-n-[[(2s)-pyrrolidin-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C)=C1NC[C@H]1NCCC1 UWCWUCKPEYNDNV-LBPRGKRZSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 125000000532 dioxanyl group Chemical group 0.000 claims description 2
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 125000005880 oxathiolanyl group Chemical group 0.000 claims description 2
- 125000003544 oxime group Chemical group 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 102000009929 raf Kinases Human genes 0.000 claims description 2
- 108010077182 raf Kinases Proteins 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 2
- 125000005503 thioxanyl group Chemical group 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000037964 urogenital cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94729107P | 2007-06-29 | 2007-06-29 | |
| US60/947,291 | 2007-06-29 | ||
| PCT/US2008/068762 WO2009006389A2 (en) | 2007-06-29 | 2008-06-30 | Pyrimidine derivatives useful as raf kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013195277A Division JP5962622B2 (ja) | 2007-06-29 | 2013-09-20 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010532380A JP2010532380A (ja) | 2010-10-07 |
| JP2010532380A5 true JP2010532380A5 (enExample) | 2012-07-26 |
| JP5649445B2 JP5649445B2 (ja) | 2015-01-07 |
Family
ID=40029124
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515219A Active JP5649445B2 (ja) | 2007-06-29 | 2008-06-30 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
| JP2013195277A Active JP5962622B2 (ja) | 2007-06-29 | 2013-09-20 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
| JP2015043208A Withdrawn JP2015117249A (ja) | 2007-06-29 | 2015-03-05 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013195277A Active JP5962622B2 (ja) | 2007-06-29 | 2013-09-20 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
| JP2015043208A Withdrawn JP2015117249A (ja) | 2007-06-29 | 2015-03-05 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US8293752B2 (enExample) |
| EP (2) | EP2167489B1 (enExample) |
| JP (3) | JP5649445B2 (enExample) |
| KR (2) | KR101650140B1 (enExample) |
| CN (3) | CN104370828B (enExample) |
| AR (1) | AR067354A1 (enExample) |
| AU (1) | AU2008273002C1 (enExample) |
| BR (1) | BRPI0813499B8 (enExample) |
| CA (1) | CA2693182C (enExample) |
| CL (1) | CL2008001933A1 (enExample) |
| DK (1) | DK3231798T3 (enExample) |
| ES (2) | ES2776169T3 (enExample) |
| IL (1) | IL202835A (enExample) |
| NZ (1) | NZ582352A (enExample) |
| RU (1) | RU2492166C2 (enExample) |
| TW (1) | TWI444379B (enExample) |
| UA (1) | UA101478C2 (enExample) |
| WO (1) | WO2009006389A2 (enExample) |
| ZA (1) | ZA200909223B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009006404A2 (en) * | 2007-06-29 | 2009-01-08 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| AU2008278966B2 (en) * | 2007-07-26 | 2012-02-23 | Novartis Ag | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
| BRPI0814975A2 (pt) * | 2007-08-08 | 2015-02-03 | Merck Serono Sa | Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla |
| FR2934265B1 (fr) * | 2008-07-23 | 2010-07-30 | Sanofi Aventis | Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique |
| EP2331095B1 (en) | 2008-08-04 | 2014-10-15 | CHDI Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| JP2012514044A (ja) * | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
| JOP20190231A1 (ar) * | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| AU2010229134A1 (en) * | 2009-03-23 | 2011-11-10 | Msd K.K. | Novel aminopyridine derivatives having Aurora A selective inhibitory action |
| AU2010229140A1 (en) * | 2009-03-24 | 2011-11-10 | Msd K.K. | Novel aminopyridine derivatives having Aurora A selective inhibitory action |
| ES2557453T3 (es) | 2009-06-09 | 2016-01-26 | Nantbioscience, Inc. | Derivados de isoquinolina, quinolina y quinazolina como inhibidores de la señalización de Hedgehog |
| CA2765044A1 (en) | 2009-06-09 | 2010-12-16 | California Capital Equity, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
| CA2765030C (en) | 2009-06-09 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| AU2010297290A1 (en) * | 2009-09-21 | 2012-03-15 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| PH12012501480A1 (en) | 2010-01-25 | 2012-10-22 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9296722B2 (en) | 2010-05-27 | 2016-03-29 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
| CN102406646B (zh) * | 2010-09-20 | 2015-09-09 | 北大方正集团有限公司 | 芳基脲衍生物用于制备治疗移植排斥药物的用途 |
| CN102153515B (zh) * | 2011-02-24 | 2013-02-27 | 中国药科大学 | N,N′-双取代脲类Raf激酶抑制剂及其制备方法和用途 |
| MX2014002459A (es) | 2011-08-30 | 2014-04-10 | Chdi Foundation Inc | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. |
| US9981918B2 (en) | 2011-08-30 | 2018-05-29 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013144923A1 (en) | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| CA2891412A1 (en) | 2012-11-20 | 2014-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| WO2014151630A2 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| DK3083627T3 (da) | 2013-12-19 | 2019-01-02 | Novartis Ag | [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis |
| UY36046A (es) | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| SG11201700341PA (en) | 2014-07-17 | 2017-02-27 | Chdi Foundation Inc | Methods and compositions for treating hiv-related disorders |
| UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2016106351A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and mtor inhibitors |
| US20180263979A1 (en) * | 2014-12-23 | 2018-09-20 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| EP3236966B1 (en) * | 2014-12-23 | 2020-08-12 | DOT Therapeutics-1, Inc. | Combination of raf inhibitors and taxanes |
| JP6666673B2 (ja) * | 2015-09-07 | 2020-03-18 | キリンホールディングス株式会社 | 細胞内送達ベヒクル |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| TW201733979A (zh) | 2015-12-11 | 2017-10-01 | Teijin Pharma Ltd | 胺基唑衍生物 |
| EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| KR101725292B1 (ko) * | 2016-03-30 | 2017-04-10 | 한국과학기술연구원 | 항암 활성을 갖는 신규 피리미딘-4-카르복시산 유도체 |
| JP2019196307A (ja) | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環アミド化合物 |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| CN110545853A (zh) * | 2017-04-28 | 2019-12-06 | 石英治疗有限公司 | Raf降解偶联化合物 |
| CA3057969A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| MX391164B (es) * | 2017-05-30 | 2025-03-21 | Dot Therapeutics 1 Inc | Metodo para producir compuesto opticamente activo |
| WO2019133810A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3962484A4 (en) | 2019-05-03 | 2023-01-18 | Kinnate Biopharma Inc. | RAF KINASE INHIBITORS |
| AU2020276695B2 (en) | 2019-05-13 | 2025-12-18 | Novartis Ag | New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer |
| EP4045498B1 (en) * | 2019-10-14 | 2025-12-03 | The Regents of the University of California | Broad spectrum anti-cancer compounds |
| BR112022007612A2 (pt) * | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| EP4065122A4 (en) * | 2019-11-27 | 2023-12-27 | Day One Biopharmaceuticals, Inc. | Solid dispersion of pan-raf kinase inhibitor |
| JPWO2021117759A1 (enExample) * | 2019-12-10 | 2021-06-17 | ||
| CA3174992A1 (en) * | 2020-03-02 | 2021-09-10 | Sironax Ltd. | Ferroptosis inhibitors - diarylamine para-acetamides |
| JP2023525349A (ja) | 2020-05-12 | 2023-06-15 | バイエル、アクチエンゲゼルシャフト | 殺真菌性化合物としてのトリアジンおよびピリミジン（チオ）アミド化合物 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| WO2022226261A1 (en) | 2021-04-23 | 2022-10-27 | Kinnate Biopharma Inc. | Treatment of cancer with a raf inhibitor |
| US12404242B2 (en) | 2021-12-17 | 2025-09-02 | Reglagene, Inc. | Compositions and methods for making and using small molecules in the treatment of cancer |
| EP4673130A1 (en) | 2023-02-28 | 2026-01-07 | Reglagene, Inc. | Compositions and methods for making and using small molecules for the treatment of health conditions |
| CN117567388B (zh) * | 2023-11-14 | 2024-04-16 | 济南悟通生物科技有限公司 | 一种2-乙酰基-5-噻唑甲酸的合成方法 |
| CN119241530A (zh) * | 2024-09-20 | 2025-01-03 | 武汉九州钰民医药科技有限公司 | 一种Tovorafenib的药物合成工艺 |
| CN119241529A (zh) * | 2024-09-20 | 2025-01-03 | 武汉九州钰民医药科技有限公司 | 一种Tovorafenib的制备方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US5563158A (en) | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| WO1997011705A1 (en) | 1995-09-26 | 1997-04-03 | Takeda Chemical Industries, Ltd. | Phosphorylamides, their preparation and use |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| JP2000501105A (ja) | 1995-12-22 | 2000-02-02 | デュポン ファーマシューティカルズ カンパニー | 新規なインテグリン受容体アンタゴニスト |
| CA2249607A1 (en) | 1996-04-03 | 1997-10-09 | Neville J. Anthony | Inhibitors of farnesyl-protein transferase |
| US5872136A (en) | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| IL126558A (en) | 1996-05-20 | 2002-07-25 | Darwin Discovery Ltd | Benzofuran carboxamides and pharmaceutical compositions containing them |
| US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| DK0944616T3 (da) * | 1996-11-15 | 2003-09-29 | Darwin Discovery Ltd | Bicykliske arylcarboxamider og deres terapeutiske anvendelse |
| US6017925A (en) | 1997-01-17 | 2000-01-25 | Merck & Co., Inc. | Integrin antagonists |
| AU6422798A (en) | 1997-03-25 | 1998-10-20 | Takeda Chemical Industries Ltd. | Stabilized urease inhibitor |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| JPH11209366A (ja) | 1998-01-23 | 1999-08-03 | Nissan Chem Ind Ltd | クロマン誘導体及び心不全治療薬 |
| EP0982030A3 (en) | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| EP1058549A4 (en) | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| WO2000053602A1 (en) | 1999-03-10 | 2000-09-14 | Merck & Co., Inc. | 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| JP2002538208A (ja) | 1999-03-10 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物 |
| WO2000058300A1 (en) | 1999-03-25 | 2000-10-05 | Nissan Chemical Industries, Ltd. | Chroman derivatives |
| DE19915364A1 (de) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Verwendung von Arylalkanoylpyridazinen |
| US6127382A (en) | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| EP1235807A1 (en) | 1999-11-24 | 2002-09-04 | Millennium Pharmaceuticals, Inc. | B-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa |
| GB0007245D0 (en) | 2000-03-24 | 2000-05-17 | Zeneca Ltd | Chemical compounds |
| AU7002501A (en) | 2000-06-21 | 2002-01-02 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| US7259157B2 (en) * | 2001-04-03 | 2007-08-21 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists |
| CA2471566A1 (en) | 2002-01-10 | 2003-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of mtp inhibitors or apob-secretion inhibitors with fibrates for use as pharmaceuticals |
| US20040048866A1 (en) | 2002-03-08 | 2004-03-11 | Teodozyj Kolasa | Indazole derivatives that are activators of soluble guanylate cyclase |
| US7202244B2 (en) | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| WO2004000820A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| AU2003246587A1 (en) * | 2002-07-02 | 2004-01-23 | F. Hoffmann-La Roche Ag | 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| WO2004028526A1 (ja) | 2002-09-25 | 2004-04-08 | Santen Pharmaceutical Co., Ltd. | ベンズアミド誘導体を有効成分とするリウマチ治療剤 |
| DE50309381D1 (de) * | 2002-11-02 | 2008-04-24 | Sanofi Aventis Deutschland | Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen |
| JP2004161716A (ja) | 2002-11-15 | 2004-06-10 | Takeda Chem Ind Ltd | Ｊｎｋ阻害剤 |
| JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
| JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | ４−オキソキノリン誘導体を含有する医薬組成物 |
| DE10328999B4 (de) | 2003-06-27 | 2006-08-31 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von Metallkomplexpigmenten mit niedriger Dispergierhärte |
| ES2317031T3 (es) | 2003-07-16 | 2009-04-16 | Janssen Pharmaceutica Nv | Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3. |
| AU2004260738B2 (en) | 2003-07-16 | 2009-07-16 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| US7189729B2 (en) | 2003-09-30 | 2007-03-13 | Irm Llc | Methods and compositions as protein kinase inhibitors |
| ZA200602666B (en) | 2004-01-12 | 2007-09-26 | Cytopia Res Pty Ltd | Selective kinase inhibitors |
| WO2005072733A1 (en) | 2004-01-20 | 2005-08-11 | Millennium Pharmaceuticals, Inc. | Dyarylurea compounds as chk-1 inhibitors |
| GB0403635D0 (en) * | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
| US7348346B2 (en) * | 2004-03-08 | 2008-03-25 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| WO2006040568A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as b raf inhibitors |
| EP2332527A3 (en) | 2004-10-20 | 2011-11-16 | Resverlogix Corp. | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases |
| CN101094829B (zh) * | 2004-12-07 | 2012-02-08 | 富山化学工业株式会社 | 新的氨茴酸衍生物或其盐 |
| WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| WO2006074057A2 (en) | 2004-12-30 | 2006-07-13 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| US7563781B2 (en) | 2005-01-14 | 2009-07-21 | Janssen Pharmaceutica Nv | Triazolopyrimidine derivatives |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2006101977A2 (en) * | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
| PL1966151T3 (pl) * | 2005-12-13 | 2012-02-29 | Merck Sharp & Dohme | Policykliczne pochodne indazoli jako inhibitory ERK |
| WO2007076474A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| TW200804349A (en) | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
| WO2007079199A2 (en) | 2005-12-30 | 2007-07-12 | Alantos Pharmaceuticals, Holding, Inc. | Substituted bis-amide metalloprotease inhibitors |
| WO2007087443A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| CA2639913A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceutical Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| US7951824B2 (en) | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
| CA2669695C (en) | 2006-11-13 | 2012-10-30 | Synta Pharmaceuticals Corp. | Tetrahydropyridinyl compounds for inflammation and immune-related uses |
| TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| WO2009006404A2 (en) | 2007-06-29 | 2009-01-08 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
-
2008
- 2008-06-27 CL CL2008001933A patent/CL2008001933A1/es unknown
- 2008-06-27 AR ARP080102801A patent/AR067354A1/es active IP Right Grant
- 2008-06-27 TW TW097124450A patent/TWI444379B/zh active
- 2008-06-30 NZ NZ582352A patent/NZ582352A/en not_active IP Right Cessation
- 2008-06-30 BR BRPI0813499A patent/BRPI0813499B8/pt active IP Right Grant
- 2008-06-30 AU AU2008273002A patent/AU2008273002C1/en active Active
- 2008-06-30 JP JP2010515219A patent/JP5649445B2/ja active Active
- 2008-06-30 DK DK17168722.1T patent/DK3231798T3/da active
- 2008-06-30 CN CN201410466320.6A patent/CN104370828B/zh active Active
- 2008-06-30 EP EP08772238.5A patent/EP2167489B1/en active Active
- 2008-06-30 WO PCT/US2008/068762 patent/WO2009006389A2/en not_active Ceased
- 2008-06-30 CN CN201611139456.1A patent/CN106957314B/zh active Active
- 2008-06-30 UA UAA200913589A patent/UA101478C2/ru unknown
- 2008-06-30 KR KR1020097027037A patent/KR101650140B1/ko active Active
- 2008-06-30 RU RU2009149214/04A patent/RU2492166C2/ru active
- 2008-06-30 EP EP17168722.1A patent/EP3231798B1/en active Active
- 2008-06-30 CA CA2693182A patent/CA2693182C/en active Active
- 2008-06-30 KR KR1020167004471A patent/KR101764076B1/ko active Active
- 2008-06-30 ES ES17168722T patent/ES2776169T3/es active Active
- 2008-06-30 ES ES08772238.5T patent/ES2635729T3/es active Active
- 2008-06-30 US US12/164,762 patent/US8293752B2/en active Active
- 2008-06-30 CN CN200880022788.9A patent/CN101784545B/zh active Active
-
2009
- 2009-12-20 IL IL202835A patent/IL202835A/en active IP Right Grant
- 2009-12-23 ZA ZA2009/09223A patent/ZA200909223B/en unknown
-
2012
- 2012-10-22 US US13/657,506 patent/US8802657B2/en active Active
-
2013
- 2013-09-20 JP JP2013195277A patent/JP5962622B2/ja active Active
-
2014
- 2014-07-28 US US14/444,007 patent/US9556177B2/en active Active
-
2015
- 2015-03-05 JP JP2015043208A patent/JP2015117249A/ja not_active Withdrawn
-
2016
- 2016-12-15 US US15/380,515 patent/US9920048B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010532380A5 (enExample) | ||
| JP7631434B2 (ja) | セレブロン（ｃｒｂｎ）に対するリガンド | |
| RU2009149214A (ru) | Соединения, подходящие для применения в качестве ингибиторов киназы raf | |
| JP6147799B2 (ja) | Ｐａｒｐインヒビターとの組合せ療法 | |
| JP5064024B2 (ja) | イマチニブの製造方法、及び該方法により製造されたイマチニブ | |
| RU2564527C2 (ru) | Производное фталазинонкетона, способ его получения и его фармацевтическое применение | |
| JP2024041923A (ja) | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 | |
| JP2010532381A5 (enExample) | ||
| AU2020368392B2 (en) | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | |
| IL263752A (en) | Training modulating compounds | |
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| JP2012514044A5 (enExample) | ||
| JP7162915B2 (ja) | 置換ピラゾロ［１，５－ａ］ピリミジン系大環状化合物 | |
| IL300308A (en) | Low molecular weight protein complexes and their applications | |
| CN114853754A (zh) | 一种硫代酰胺衍生物及其制备方法和应用 | |
| JP2021520418A (ja) | 高活性ｃｓｆ１ｒ阻害薬化合物 | |
| CN101531653B (zh) | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 | |
| JP2021501215A (ja) | アミノ置換窒素含有縮合環化合物、その調製方法及び使用 | |
| WO2017200902A1 (en) | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | |
| JP5319284B2 (ja) | 誘導物及びその各種薬学的に受容可能な塩、５Ｈ−チエノ［３，４−ｃ］ピロール−４，６ジオン誘導物、その調整方法、その使用 | |
| JP2019509267A (ja) | テトラヒドロイソキノリン誘導体 | |
| CN118695863A (zh) | 靶向swi/snf相关的基质关联的肌动蛋白依赖性染色质调控因子亚家族a成员4(smarca4) | |
| JP2006518767A (ja) | フラボン酢酸類似体およびその使用方法 | |
| US20110060010A1 (en) | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof | |
| CN103214467B (zh) | 5-[[4-[(2,3-二甲基-2h-吲唑-6-基)甲氨基]-2嘧啶基]氨基]-2-甲基-苯磺酰胺衍生物及其制备方法与应用 |